With $161M In Funding, Somalogic Shifting Focus to Dx and Wellness Products

Thursday, May 25, 2017


miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma

Wednesday, May 24, 2017

BOULDER, CO, May 24, 2017 (GLOBE NEWSWIRE) – miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the European Commission (EC) granted orphan medicinal product designation to miRagen’s product candidate, MRG-106, for the treatment of cutaneous T-cell lymphoma (CTCL). CTCL occurs when certain types of T-cells become cancerous and cause debilitating tumors in the skin and in other parts of the body. 

Colorado BioScience Association appoints new board leadership

Wednesday, May 24, 2017

Terumo BCT General Counsel Scott Larson named chairman of the board  

ClearSight Announces Sale of Parent Company, Sharklet Technologies

Monday, May 22, 2017

AURORA, Colo.--(BUSINESS WIRE)--ClearSight LLC is pleased to announce the acquisition of its parent company Sharklet Technologies, Inc., by Peaceful Union, an equity medical device firm in Hangzhou, China. ClearSight LLC was co-founded by Drs. Kevin Cuevas and Shravanthi Reddy to develop the next generation intraocular lens (IOL) implant. 

New Study Shows Advanced Diagnostic Tests, Including the VeriStrat® Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients

Monday, May 22, 2017

Biodesix’s VeriStrat® Test Is Cost Saving, Can Help Optimize End-of-Life Care

Continue Reading

Vivaldi Biosciences Board Appoints William Wick as Chief Executive Officer and John Costantino as Chairman

Monday, May 22, 2017

Fort Collins, CO – Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing genetically attenuated live influenza vaccines for seasonal and pandemic influenza, today announced the appointment of William O. Wick, Jr. to the position of Chief Executive Officer. John R. Costantino, Managing General Partner of NGN Capital LLC, was appointed Chairman of the Board of Directors. 

Terumo BCT Announces Enrollment of the First Patient in Its U.S. Clinical Trial Designed to Study Platelets Treated With the Mirasol® Pathogen Reduction Technology (PRT) System

Wednesday, May 17, 2017

MIPLATE Clinical Trial to Compare the Clinical Effectiveness of Standard Platelets Versus Pathogen-Reduced Platelets  

miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting

Wednesday, May 17, 2017

New Phase 1 data will be released including safety, efficacy and pharmacokinetics after intravenous and subcutaneous administration in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) 

Ventria Bioscience announces peer-reviewed publication on novel mechanism of action in inflammatory bowel disease

Wednesday, May 17, 2017

Collaboration with Children’s Hospital Colorado finds Ventria’s recombinant human lactoferrin modulates immune response 

Sharklet Technologies Announces Acquisition by Peaceful Union and New Partnership to Accelerate Development of Medical Devices and Surface Technologies Featuring Sharklet®

Tuesday, May 16, 2017

AURORA, COLO. – Sharklet Technologies, Inc., a biotechnology company lauded for the creation and commercialization of Sharklet®, the world’s first micro-texture that inhibits bacterial growth on surfaces, today announced that it has completed a financing event led by Peaceful Union, an equity medical device firm in Hangzhou, China. Terms of the transaction were not disclosed.